AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2288326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 7025830 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (2.5 ml of 40% alc/kg)
Number of subjects: 18
Study 7025830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31679431 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuweibuqi (LWBQ) capsules (low dose: 1 LWBQ capsule + 8 starch capsules; medium dose: 3 LWBQ capsules + 6 starch capsules; high dose: 9 LWBQ capsules) for 30 days, 3 times a day
Number of subjects: 429
Study 31679431 — intervention group
Group type: COMPARATOR
Intervention: Starch capsules (control group)
Number of subjects: 429
Study 30419868 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated neuromuscular inhibition technique (INIT) + denneroll cervical traction device
Number of subjects: 120
Study 30419868 — intervention group
Group type: COMPARATOR
Intervention: Integrated neuromuscular inhibition technique (INIT)
Number of subjects: 120
Study 26875161 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fire safety checks program (HFSC)
Number of subjects: 2
Study 26875161 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar characteristics to intervention group)
Number of subjects: 2
Study 24970742 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (MT)
Number of subjects: 101
Study 24970742 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (CT)
Number of subjects: 101
Study 22124355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (HIT) protocols with different work-to-rest ratios (30/30, 60/30, 90/30, 60/60)
Number of subjects: 8
Study 22124355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (HIT) protocols
Number of subjects: 8
Study 22124355 — intervention group
Group type: COMPARATOR
Intervention: Steady-state exercise at 70% VO2max
Number of subjects: 8
Study 19129751 — intervention group
Group type: EXPERIMENTAL
Intervention: EVT 301 (25 mg)
Number of subjects: 20
Study 19129751 — intervention group
Group type: EXPERIMENTAL
Intervention: EVT 301 (75 mg)
Number of subjects: 20
Study 19129751 — intervention group
Group type: EXPERIMENTAL
Intervention: EVT 301 (150 mg)
Number of subjects: 20
Study 19129751 — intervention group
Group type: COMPARATOR
Intervention: Selegiline (10 mg)
Number of subjects: 20
Study 19129751 — intervention group
Group type: EXPERIMENTAL
Intervention: EVT 301 (75 mg) in AD subjects
Number of subjects: 20
Study 17957909 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch
Number of subjects: 96
Study 17957909 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (ethinyl estradiol 30 microg and levonorgestrel 150 microg)
Number of subjects: 96
Study 15140020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 11
Study 15140020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 11
Study 15140020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 11
Study 12008682 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (once daily)
Number of subjects: 349
Study 12008682 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin (once or twice daily)
Number of subjects: 349
Study 10477441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ppm ozone
Number of subjects: 0
Study 10477441 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 0
Study 10477441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 ppm ozone
Number of subjects: 0
Study 10477441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure
Number of subjects: 0
Study 10477441 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, 975 mg)
Number of subjects: 0
Study 7539854 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg, 8 mg, and 12 mg
Number of subjects: 248
Study 7539854 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg and 12 mg
Number of subjects: 248
Study 7539854 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 248
Study 7539854 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (all doses)
Number of subjects: 248
Study 7539854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 2278720 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose metoclopramide (M)
Number of subjects: 165
Study 2278720 — intervention group
Group type: COMPARATOR
Intervention: Chloropromazine (C)
Number of subjects: 165
Study 2278720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (D) with M
Number of subjects: 165
Study 2278720 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloropromazine (C) with D
Number of subjects: 165
Study 110185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 30
Study 110185 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 31053887 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory Training (WMT)
Number of subjects: 140
Study 31053887 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback Training (NFT) + Working Memory Training (WMT)
Number of subjects: 140
Study 31053887 — intervention group
Group type: COMPARATOR
Intervention: Visual Search Training (Active Control)
Number of subjects: 140
Study 31053887 — intervention group
Group type: COMPARATOR
Intervention: Silent Control Group (no training)
Number of subjects: 140
Study 30557941 — intervention group
Group type: EXPERIMENTAL
Intervention: MVS + surgical ablation
Number of subjects: 260
Study 30557941 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial maze
Number of subjects: 260
Study 30557941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Number of subjects: 260
Study 30557941 — intervention group
Group type: COMPARATOR
Intervention: MVS alone
Number of subjects: 260
Study 28234969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (home-based adherence support)
Number of subjects: 870
Study 28234969 — intervention group
Group type: COMPARATOR
Intervention: Standard care/control arm
Number of subjects: 870
Study 25872794 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Early Warning System (MEWS) chart with training program
Number of subjects: 114
Study 25872794 — intervention group
Group type: COMPARATOR
Intervention: Standard care without training
Number of subjects: 114
Study 23837939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide pulse therapy (CPT)
Number of subjects: 60
Study 23837939 — intervention group
Group type: COMPARATOR
Intervention: Daily oral prednisolone
Number of subjects: 60
Study 21383283 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (BV)
Number of subjects: 1237
Study 21383283 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 1237
Study 20035587 — intervention group
Group type: EXPERIMENTAL
Intervention: Equasym XL/Metadate CD
Number of subjects: 184
Study 20035587 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerta
Number of subjects: 184
Study 20035587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 184
Study 16872789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 148
Study 16872789 — intervention group
Group type: COMPARATOR
Intervention: Tai-Chi interest class (comparison group)
Number of subjects: 148
Study 17163895 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic literature review process
Number of subjects: 0
Study 17163895 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assessment questionnaire
Number of subjects: 0
Study 17163895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissemination strategies
Number of subjects: 0
Study 15543081 — intervention group
Group type: EXPERIMENTAL
Intervention: lercanidipine 10 mg
Number of subjects: 23
Study 15543081 — intervention group
Group type: EXPERIMENTAL
Intervention: lercanidipine 20 mg
Number of subjects: 23
Study 15543081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 23
Study 10517716 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7705
Study 10517716 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d
Number of subjects: 7705
Study 10517716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 10517716 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (combined 60 mg/d and 120 mg/d)
Number of subjects: 7705
Study 10517716 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 7705
Study 8529160 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% idoxuridine ointment
Number of subjects: 80
Study 8529160 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% trifluorothymidine ointment
Number of subjects: 80
Study 8529160 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acyclovir ointment
Number of subjects: 80
Study 8529160 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% bromovinyldeoxyuridine (BVDU) ointment
Number of subjects: 80
Study 1837785 — intervention group
Group type: EXPERIMENTAL
Intervention: high-fat/low-carbohydrate diet
Number of subjects: 24
Study 1837785 — intervention group
Group type: EXPERIMENTAL
Intervention: low-fat/high-carbohydrate diet
Number of subjects: 24
Study 6752467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole (CMZ)
Number of subjects: 172
Study 6752467 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (CEZ)
Number of subjects: 172
Study 29380922 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who developed superimposed pre-eclampsia (SPE)
Number of subjects: 97
Study 29380922 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who delivered a small-for-gestational-age (SGA) infant
Number of subjects: 97
Study 29380922 — intervention group
Group type: COMPARATOR
Intervention: Women of black ethnicity
Number of subjects: 97
Study 28705190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (80 mg once daily)
Number of subjects: 406
Study 28705190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 28705190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 406
Study 26316434 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) 1000 mg once daily for 12 months
Number of subjects: 108
Study 26316434 — intervention group
Group type: COMPARATOR
Intervention: Placebo with recommended diet and lifestyle intervention for 12 months
Number of subjects: 108
Study 23432755 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine (CSA) and mycophenolate mofetil (MMF) (CSA/MMF, n=151)
Number of subjects: 440
Study 23432755 — intervention group
Group type: EXPERIMENTAL
Intervention: high-level tacrolimus (TAC, 8-12 μg/L) and low-level sirolimus (SIR, 3-7 μg/L) (TACH/SIRL, n=149)
Number of subjects: 440
Study 23432755 — intervention group
Group type: EXPERIMENTAL
Intervention: low-level TAC (3-7 μg/L) and high-level SIR (8-12 μg/L) (TACL/SIR(H), n=140)
Number of subjects: 440
Study 21242652 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry beverage
Number of subjects: 24
Study 21242652 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 24
Study 21242652 — intervention group
Group type: COMPARATOR
Intervention: Strawberry beverage and Placebo beverage
Number of subjects: 24
Study 19617271 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 842
Study 19617271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 842
Study 17179021 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR AVSH 60‐130 programming
Number of subjects: 988
Study 17179021 — intervention group
Group type: COMPARATOR
Intervention: VVI‐40 programming
Number of subjects: 988
Study 15138344 — intervention group
Group type: COMPARATOR
Intervention: Hematological supportive care measures including supplementation with iron, human erythropoietin, interleukin 11, granulocyte colony-stimulating factor, and autologous or allogeneic stem cell rescue.
Number of subjects: 14
Study 15138344 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (matched pairs treated in hospitals not belonging to Jehovah's Witnesses).
Number of subjects: 14
Study 15138344 — intervention group
Group type: COMPARATOR
Intervention: Review of 50 pediatric and adult oncological patients belonging to Jehovah's Witnesses from international literature.
Number of subjects: 14
Study 11789591 — intervention group
Group type: EXPERIMENTAL
Intervention: SKI 306X 200 mg t.i.d.
Number of subjects: 96
Study 11789591 — intervention group
Group type: EXPERIMENTAL
Intervention: SKI 306X 400 mg t.i.d.
Number of subjects: 96
Study 11789591 — intervention group
Group type: EXPERIMENTAL
Intervention: SKI 306X 600 mg t.i.d.
Number of subjects: 96
Study 11789591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 9677830 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (IgM)
Number of subjects: 81
Study 9677830 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (IgG and IgM) measured at 6 months
Number of subjects: 81
Study 7997002 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 10
Study 7997002 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppb nitrogen dioxide
Number of subjects: 10
Study 7997002 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ppb nitrogen dioxide
Number of subjects: 10
Study 30064403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP) only
Number of subjects: 45
Study 30064403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP) + splint
Number of subjects: 45
Study 30064403 — intervention group
Group type: COMPARATOR
Intervention: Splint only
Number of subjects: 45
Study 27296249 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention providing access to a virtual online clinic with videos about inpatient rehabilitation (n=394).
Number of subjects: 788
Study 27296249 — intervention group
Group type: COMPARATOR
Intervention: No special treatment preparation (control group, n=394).
Number of subjects: 788
Study 24127304 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HPV self-test
Number of subjects: 8800
Study 24127304 — intervention group
Group type: COMPARATOR
Intervention: Telephone call
Number of subjects: 8800
Study 24127304 — intervention group
Group type: COMPARATOR
Intervention: Standard screening invitation routine (Control)
Number of subjects: 8800
Study 23687231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 5% in lactated Ringer's solution (group D; n = 87)
Number of subjects: 162
Study 23687231 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (group P; n = 75)
Number of subjects: 162
Study 23687231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 5% in lactated Ringer's solution (group D)
Number of subjects: 162
Study 23687231 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (group P)
Number of subjects: 162
Study 20876454 — intervention group
Group type: EXPERIMENTAL
Intervention: LEN-DEX (lenalidomide plus dexamethasone)
Number of subjects: 192
Study 20876454 — intervention group
Group type: COMPARATOR
Intervention: PLC-DEX (placebo plus dexamethasone)
Number of subjects: 192
Study 18492837 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO treatment
Number of subjects: 20
Study 18492837 — intervention group
Group type: COMPARATOR
Intervention: CHO treatment
Number of subjects: 20
Study 16793810 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg controlled and extended release)
Number of subjects: 921
Study 16793810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921
Study 16793810 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 921
Study 12705176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 300 mg
Number of subjects: 12
Study 12705176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 450 mg
Number of subjects: 12
Study 12705176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg
Number of subjects: 12
Study 10632308 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium (5 mg/d for 2 years and 10 mg/d for the third year)
Number of subjects: 2027
Study 10632308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2027
Study 10632308 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Number of subjects: 2027
Study 14588415 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulators with warning
Number of subjects: 87
Study 14588415 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulators without warning
Number of subjects: 87
Study 14588415 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 8244360 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 125
Study 8244360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid
Number of subjects: 125
Study 8244360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 3009077 — intervention group
Group type: EXPERIMENTAL
Intervention: Beet-fibre meal (10.8 g dietary fibre from sugar beet)
Number of subjects: 0
Study 3009077 — intervention group
Group type: COMPARATOR
Intervention: Control meal (without beet-fibre)
Number of subjects: 0
Study 3009077 — intervention group
Group type: EXPERIMENTAL
Intervention: Beet-fibre meal
Number of subjects: 0
Study 3009077 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 0
Study 31128875 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap followed by MCV4-CRM197 (+PCV13) 3–4 weeks later (Group A)
Number of subjects: 107
Study 31128875 — intervention group
Group type: EXPERIMENTAL
Intervention: All three vaccines administered in a single visit (Group B)
Number of subjects: 107
Study 31128875 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV4-CRM197 (+PCV13) followed by Tdap 3–4 weeks later (Group C)
Number of subjects: 107
Study 31128875 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 107
Study 29482642 — intervention group
Group type: EXPERIMENTAL
Intervention: High CXCL13 levels
Number of subjects: 1010
Study 29482642 — intervention group
Group type: EXPERIMENTAL
Intervention: High CXCL13 levels in triple-negative breast cancer (TNBC)
Number of subjects: 1010
Study 29482642 — intervention group
Group type: EXPERIMENTAL
Intervention: High CXCL13 levels confirmed in HE10/97 trial patient population with TNBC
Number of subjects: 1010
Study 29482642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor CD4 content
Number of subjects: 1010
Study 29482642 — intervention group
Group type: EXPERIMENTAL
Intervention: FOXP3 content
Number of subjects: 1010
Study 27776034 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal testosterone levels measured at wakeup and bedtime prior to discharge and at 3 additional times at home
Number of subjects: 86
Study 27776034 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal testosterone levels measured at wakeup and bedtime prior to discharge and at 3 additional times at home
Number of subjects: 86
Study 25453134 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 43
Study 25453134 — intervention group
Group type: COMPARATOR
Intervention: CNI
Number of subjects: 43
Study 23241361 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based nursing intervention (SOULAGE-TAVIE)
Number of subjects: 60
Study 23241361 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 20139427 — intervention group
Group type: COMPARATOR
Intervention: Oral levonorgestrel (0.75 mg x 4, at 24 h intervals on LH + 1 to LH + 4; n = 8)
Number of subjects: 15
Study 20139427 — intervention group
Group type: COMPARATOR
Intervention: Vaginal levonorgestrel (1.5 mg single dose on LH + 2; n = 7)
Number of subjects: 15
Study 18248661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal PHA (150 microg, 1.5 mg, 15 mg)
Number of subjects: 5
Study 18248661 — intervention group
Group type: COMPARATOR
Intervention: Heat-inactivated PHA
Number of subjects: 5
Study 18248661 — intervention group
Group type: COMPARATOR
Intervention: CCK(1) receptor antagonist dexloxiglumide
Number of subjects: 5
Study 18248661 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 5
Study 16203879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (36 mg twice daily)
Number of subjects: 1949
Study 16203879 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target INR 2.5)
Number of subjects: 1949
Study 11902626 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming environmental values
Number of subjects: 0
Study 11902626 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced self-focus
Number of subjects: 0
Study 11902626 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-activation and centrality measures
Number of subjects: 0
Study 10201726 — intervention group
Group type: EXPERIMENTAL
Intervention: Planet Health intervention
Number of subjects: 1295
Study 7844607 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy with cisplatin 60 mg/m2 and epirubicin 110 mg/m2 administered at 3-week intervals for three cycles, followed by pelvic radiotherapy.
Number of subjects: 260
Study 7844607 — intervention group
Group type: COMPARATOR
Intervention: Standard pelvic radiotherapy alone.
Number of subjects: 260
Study 7844607 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment (chemotherapy followed by radiotherapy).
Number of subjects: 260
Study 2333832 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral caffeine
Number of subjects: 0
Study 2333832 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral caffeine
Number of subjects: 0
Study 2333832 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral caffeine
Number of subjects: 0
Study 2333832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 313353 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vasopressin (IVV) started at 0.3 U/min, increased to 1.5 U/min as needed
Number of subjects: 22